RNAC - Cartesian Therapeutics - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8162121045
mRNA, Cell, Therapies, Autoimmune, Diseases
Cartesian Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing innovative mRNA cell therapies to treat autoimmune diseases. By harnessing the power of messenger RNA (mRNA), the company aims to revolutionize the treatment of these debilitating conditions.
The company's lead product candidate, Descartes-08, is an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy currently in Phase 2b clinical development. This therapy has shown promising results in treating generalized myasthenia gravis, a chronic autoimmune disorder that affects the nervous system. Additionally, Cartesian Therapeutics is exploring the potential of Descartes-08 in treating systemic lupus erythematosus and multiple myeloma, as well as other autoimmune diseases through its autoimmune basket trials.
Cartesian Therapeutics is also advancing its pipeline with Descartes-15, which is being developed to treat autoimmune diseases and multiple myeloma. Furthermore, the company has Descartes-33 in preclinical development, which holds promise for the treatment of autoimmune diseases. By targeting the root causes of these diseases, Cartesian Therapeutics aims to improve the lives of millions of people worldwide.
Headquartered in Gaithersburg, Maryland, Cartesian Therapeutics Inc. is at the forefront of mRNA cell therapy innovation. With a strong focus on research and development, the company is poised to make a significant impact in the treatment of autoimmune diseases. For more information, please visit their website at https://www.cartesiantherapeutics.com.
Drawdown (Underwater) Chart
RNAC Stock Overview
Market Cap in USD | 576m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2016-06-22 |
RNAC Stock Ratings
Growth 5y | -61.9 |
Fundamental | -5.61 |
Dividend | |
Rel. Performance vs Sector | -8.23 |
Analysts | 4.43/5 |
Fair Price Momentum | 19.36 USD |
Fair Price DCF | - |
RNAC Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
RNAC Growth Ratios
Growth Correlation 3m | 82.5% |
Growth Correlation 12m | -48.3% |
Growth Correlation 5y | -79.4% |
CAGR 5y | -12.74% |
CAGR/Mean DD 5y | -0.23 |
Sharpe Ratio 12m | 0.12 |
Alpha vs SP500 12m | -103.37 |
Beta vs SP500 5y weekly | 1.56 |
ValueRay RSI | 80.80 |
Volatility GJR Garch 1y | 80.85% |
Price / SMA 50 | 25.85% |
Price / SMA 200 | 9.69% |
Current Volume | 55.6k |
Average Volume 20d | 123.2k |
External Links for RNAC Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 22.30 with a total of 55,570 shares traded.
Over the past week, the price has changed by -1.11%, over one month by +31.18%, over three months by +29.80% and over the past year by -40.53%.
According to ValueRays Forecast Model, RNAC Cartesian Therapeutics will be worth about 21.8 in October 2025. The stock is currently trading at 22.30. This means that the stock has a potential downside of -2.2%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 43 | 92.8 |
Analysts Target Price | 3.5 | -84.3 |
ValueRay Target Price | 21.8 | -2.20 |